Report LibraryAll Reports
Datamonitor Healthcare Infectious Diseases Disease Analysis: Meningococcal Vaccines
February 22, 2021
The US meningococcal vaccines market is expected to grow over the forecast period due to incremental increases in MenACWY and MenB
coverage rates in adolescents and young adults before the anticipated introduction of GlaxoSmithKline’s and Pfizer’s pentavalent vaccines in H2
2023 and H1 2024, respectively. Beyond this period, market growth will be driven by the uptake of pentavalent vaccines, which could significantly
boost coverage for the MenB component by linking the higher coverage rates observed with the booster dose of MenACWY in adolescents (53.7%
in 2019) to the suboptimal coverage rates with MenB vaccines (21.8% of 17-year-olds received at least one MenB dose in 2019). The pentavalent
vaccines would also be more convenient for physicians and patients as they would reduce the total number of doses required during adolescence
from four (two MenACWY + two MenB) to three.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Meningococcal Vaccines and Other Meningococcus-Specific Agents (Antibacterial)|